Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Epilepsy and seizure classification

Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy.

Jun Wang; Lan Tan; Lin Tan; Yan Tian; Jing Ma; Chen-Chen Tan; Hui-Fu Wang; Ying Liu; Meng-Shan Tan; Teng Jiang; Jin-Tai Yu

Originally published in Scientific reports · 2015-05-18

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

MicroRNAs (miRNAs) open up a new field for molecular diagnosis for cancer and other diseases based on their stability in serum. However, the role of circulating miRNAs in plasma/serum in epilepsy diagnosis is still unclear. The aim of this study was to evaluate whether miRNAs can be used as biomarkers for drug-resistant epilepsy. We measured the differences in serum miRNA levels between 30 drug-resistant patients and 30 drug-responsive epilepsy patients in discovery and training phases using Illumina HiSeq2000 sequencing followed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assays. The selected miRNAs were then validated in 77 drug-resistant epilepsy patients, 81 drug-responsive epilepsy patients and 85 healthy controls by qRT-PCR. We found that circulating miRNAs are differentially expressed between drug-resistant group and drug-responsive group. MiR-194-5p, -301a-3p, -30b-5p, -342-5p and -4446-3p were significantly deregulated in drug-resistant group compared to drug-responsive group and control group.

Discussion

To date, the diagnosis and treatment of drug-resistant epilepsy still suffer from a lack of reliable biomarkers, despite ample efforts have been made21,22,23. While in recent years, miRNAs have gained significant attention and have been proposed as novel biomarkers for the diagnosis of several diseases including some CNS diseases4,6,7,8,9,20 for several reasons. First, miRNAs have been found stable in serum, and the test of miRNAs in blood is broadly accessible, rapid, noninvasive, and economical.

Editorial reading guide

  • Which patient population and reference standard did the authors use?
  • Was the finding validated in a separate cohort, and how might patient selection affect it?